Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Gastric Cancer
Multidisciplinary Management of Gastric Cancer
Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care. Treatment for localized disease requires surgical resection with neoadjuvant and/or adjuvant therapy as indicated, while advanced disease is typically treated with systemic therapy with or without radiation. Optimal treatment for resectable disease requires clinician awareness of current evidence regarding the recurrence and survival rates associated with various combined modality approaches. Decisions regarding treatment for advanced or metastatic gastric cancer require that clinicians be familiar with existing and new systemic therapies and targeted therapies as well as the most effective and tolerable combination regimens. Clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies become available.
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Recognize the importance of multidisciplinary care for patients with gastric cancer.
- Select the optimal treatment approach for patients with various presentations of gastric cancer.
- Review current evidence for treating advanced gastric cancer with targeted therapies to make informed treatment decisions.
Jaffer A. Ajani, MD
The University of Texas MD Anderson Cancer Center
George A. Poultsides, MD, MS
Stanford Cancer Institute
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses no relevant financial relationships:
George A. Poultsides, MD, MS
The faculty listed below discloses the following relevant financial relationships:
Jaffer A. Ajani, MD
Acrotech Biopharma, LLC: Scientific Advisor; Honoraria
Astellas Pharma US, Inc.: Scientific Advisor; Grant/Research Support; Honoraria
AstraZeneca Pharmaceuticals LP: Scientific Advisor; Honoraria
BeiGene: Scientific Advisor; Honoraria
Jaffar A. Ajani, MD (cont.)
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support; Honoraria
DAVA Pharmaceuticals, Inc.: Scientific Advisor; Honoraria
Delta Fly, Japan: Grant/Research Support
Merck & Co, Inc.: Scientific Advisor; Grant/Research Support; Honoraria
ProLynx Inc.: Grant/Research Support
Roche Laboratories, Inc.: Scientific Advisor; Grant/Research Support; Honoraria
Taiho Pharmaceuticals Co., Ltd: Scientific Advisor; Honoraria
Zymeworks: Grant/Research Support
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Lisa Gurski, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-20-123-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until November 5, 2021. PAs should only claim credit commensurate with the extent of their participation.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00043753; Approval #: 200138668
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing